Drug Profile
Research programme: neurological disorder therapeutics - Cure Network Dolby Acceleration Partners
Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Gladstone Institutes
- Developer BioMotiv; Cure Network Dolby Acceleration Partners
- Class Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Ion channel modulators; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Dravet syndrome; Epilepsy
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Dravet-syndrome in USA
- 28 Sep 2022 No recent reports of development identified for research development in Epilepsy in USA
- 28 Aug 2019 No recent reports of development identified for research development in Alzheimer's-disease in Germany